RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
RHYTHM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$88.23+2.06 (+2.39%)
Close on Oct 19, 2026
- Market cap
- $6.05B
- P/E (TTM)
- –
- Dividend yield
- –
Rhythm Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $6.07B | $166.30M |
| Enterprise Value | $5.85B | $88.19M |
| PS Ratio | 25.32 | 3.65 |
| PB Ratio | 58.99 | 2.03 |
| P/TBV Ratio | 61.93 | 2.29 |
Enterprise value
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 24.38 | 2.51 |
Income (trailing twelve months)
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $239.92M | $58.34M |
| Gross Profit | $213.53M | $105.94M |
| Operating Income | -$200.63M | -$21.40M |
| Pretax Income | -$204.28M | -$14.34M |
| Net Income | -$205.35M | -$22.46M |
| EBITDA | -$200.63M | -$16.91M |
| EPS (Diluted) | -$3.11 | -$0.83 |
Margins
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 89.0% | 52.9% |
| Operating Margin | -83.6% | -44.0% |
| Pretax Margin | -85.1% | -13.3% |
| Profit Margin | -85.6% | -40.2% |
| EBITDA Margin | -83.6% | -30.2% |
Returns
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -450.9% | -53.2% |
| Return on Assets (ROA) | -50.7% | -40.9% |
| Return on Capital Employed (ROCE) | -64.0% | -38.1% |
Growth
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 53.5% | 5.96% |
| Revenue Growth (3Y CAGR) | 100.2% | 2.25% |
Balance sheet
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $330.90M | $61.43M |
| Total Debt | $106.10M | $118.52M |
| Net Cash (Debt) | $224.80M | $15.35M |
| Net Cash Per Share | $3.26 | $0.66 |
| Equity (Book Value) | $102.98M | $49.09M |
| Book Value Per Share | $1.50 | $1.37 |
| Tangible Book Value | $98.09M | $23.52M |
| Working Capital | $302.98M | $76.81M |
Financial position
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.45 | 3.34 |
| Quick Ratio | 3.00 | 2.44 |
| Debt / Equity | 1.03 | 0.52 |
| Interest Coverage | -10.86 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$105.35M | -$12.35M |
Efficiency
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.59 | 0.39 |
| Inventory Turnover | 1.07 | 2.70 |
| Revenue Per Employee | $579.51K | $404.87K |
| Profits Per Employee | -$496.01K | -$703.34K |
| Employee Count | 414 | 74 |
Dividends and yields
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -3.38% | -23.3% |
Shares
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 68,852,100 | 58,127,000 |
| Shares Change (YoY) | 8.08% | 10.9% |
| Shares Change (QoQ) | 0.54% | 0.54% |
| Float | 68,125,100 | 49,136,700 |
| Shares Held by Insiders | 1.06% | 11.6% |
| Shares Held by Institutions | 112.4% | 59.4% |
Taxes
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $1.07M | $79.87K |
Scores
| Measure | Rhythm Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 11.77 | -0.22 |
| Piotroski F-Score | 6 | 4 |
| Beneish M-Score | -2.89 | -2.62 |
Calculated by StockData from Rhythm Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.